Optimization of injectable PLGA in-situ forming implants of anti-psychotic risperidone via Box-Behnken Design
Authors:
- Tarek M. IbrahimTITarek M. Ibrahim
- Nagia A. El-MegrabNENagia A. El-Megrab
- Hanan M. El-NahasHEHanan M. El-Nahas
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 58
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga systemDARU Journal of Pharmaceutical Sciences, 2013
- Design of a long-term antipsychotic in situ forming implant and its release control method and mechanismInternational Journal of Pharmaceutics, 2012
- Injectable PLA-basedin situforming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterizationDrug Development and Industrial Pharmacy, 2012
- Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochlorideSaudi Pharmaceutical Journal, 2011
- Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett–Burman designInternational Journal of Pharmaceutics, 2010
- Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- In vitro and in vivo demonstration of risperidone implants in miceSchizophrenia Research, 2008
- Sucrose acetate isobutyrate as an In Situ forming system for sustained risperidone releaseJournal of Pharmaceutical Sciences, 2007
- Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectableEuropean Neuropsychopharmacology, 2006
- Effect of Co-Solvents on the Controlled Release of Calcitonin Polypeptide fromIn SituBiodegradable Polymer ImplantsDrug Delivery, 2005